Tianjing Biotechnology grants Sanofi the rights to Yulelimab in China with a down payment of 250 million yuan
cjczf
发表于 2024-9-26 20:15:54
3820
0
0
Beijing News Tianjing Biotech announced on its official WeChat official account on September 25 that it had reached strategic cooperation with Sanofi on the development, production and commercialization of the globally innovative CD73 antibody uliledlimab independently developed by Tianjing Biotech in Greater China.
Yulelimumab is an innovative CD73 antibody with differentiated advantages, which enhances the body's immune response to cancer cells by regulating the tumor microenvironment. At present, the drug is undergoing critical research in China in combination with trastuzumab for the treatment of advanced non-small cell lung cancer (NSCLC). At the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), Tianjing Biotechnology released data from phase 1b/2 clinical studies conducted in the United States and China. Data shows that 31% of newly diagnosed NSCLC patients have a therapeutic response to combination therapy; Among patients with high CD73 expression and PD-L1 positivity, 63% of patients responded to combination therapy. The biomarker analysis results showed that high expression of tumor CD73 is closely related to treatment response, further suggesting the potential of CD73 expression as a predictive biomarker.
According to the terms of the agreement, Sanofi will be granted the exclusive license to develop, produce and commercialize Urinary McAb in Chinese Mainland, Hong Kong, Macao and Taiwan. Tianjing Biotechnology will receive a down payment and a series of milestone payments, including two recent milestone payments. Tianjing Biotechnology will lead the clinical development of Yulelimumab for specific cancer indications, and be responsible for clinical drug supply and long-term commercial production. Sanofi will jointly bear part of the clinical development costs and lead the commercialization of the product in Greater China.
Sanofi will make a down payment of approximately 32 million euros (approximately 250 million yuan) and recent milestone payments, as well as specific registration and sales milestone payments, to Tianjing Biotechnology; The maximum potential total consideration shall not exceed 213 million euros (approximately 1.7 billion yuan). After the commercialization of the product, Tianjing Biotechnology will have the right to receive a tiered royalty based on the net sales of Yulelimab in Greater China, up to a double-digit percentage. In addition to the financial terms mentioned above, Tianjing Biotechnology will also receive additional milestone payments upon regulatory approval for each new indication of Yulelimab.
TJ Biopharma is a biotechnology company focused on innovative therapies for autoimmune diseases and tumors, committed to bringing breakthrough treatment methods to patients worldwide through cutting-edge innovation.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Alibaba sells Intime Department Store to Yagor for 7.4 billion yuan
- Yintai Department Store changes ownership! Alibaba sells at a loss of 9.3 billion yuan
- Expected loss of 9.3 billion yuan, Alibaba exits non core assets and bid farewell to Yintai
- A new round of 'slimming'? Alibaba sells Intime Department Store for 7.4 billion yuan, with frequent capital operations in the fourth quarter
- 7.4 billion yuan! Alibaba sells Intime Department Store!
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Important data from the United States has been released, and US stock indices have all closed higher! This pharmaceutical giant fell more than 17% and its market value evaporated by 597.6 billion yuan overnight; What is the situation of Bitcoin's' s
- Changan Automobile signs contract with Yihang Intelligent to invest over 20 billion yuan in developing flying cars over 5 years
- Over the next 5 years, Changan Automobile will invest more than 20 billion yuan and sign a cooperation agreement with Yihang Intelligent for flying cars
- Alibaba clears Yintai Department Store and changes ownership to Yagor for 7.4 billion yuan
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 5 小时前
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏